On November 11, API China 2026 grandly opened at the Wuhan International Expo Center. As an innovative force in the API and intermediates sector, Leadsynbio showcased our core products and new product plans, engaging with customers and industry experts to discuss technology frontiers and innovative applications, and to explore pathways for sustainable industry development.
At the show, our innovative technology achievements and diversified product portfolio drew widespread attention from attending visitors and partners. Leveraging our original innovation capabilities and full-chain strength, Leadsynbio has achieved industrial implementation of multiple proprietary processes. This year, our self-developed L-threonine aldolase (LTTA) enzymatic catalysis technology won the Second Prize of the Provincial Science and Technology Progress Award and was selected as an outstanding case of provincial future-industry innovation and development. This technology has been applied to the large-scale production of D-ethyl ester, a key intermediate for Florfenicol. Leadsynbio has also built supporting key starting-material production lines and extended downstream to Florfenicol API, forming an integrated supply capability from basic chemical raw materials to finished APIs and providing customers with high-quality, sustainable product assurance.
Looking ahead, Leadsynbio will continue to strengthen R&D and industrial-chain collaboration, translate the advantages of its synthetic biology platform into sustained multi-category innovation capabilities, and work with industry partners to build a sustainable industrial ecosystem, promoting high-quality industry development.
Next:Market | Leadsynbio shines at CPHI Milan 2026, connecting the world through green biomanufacturing

On November 11,Leadsynbio showcased our core products and new product plans at API China 2026, engaging with customers and industry experts to discuss technology frontiers and innovative applications, and to...
[ Details ]Nov 16,2026